PuSH - Publication Server of Helmholtz Zentrum München: Exploring novel GSK-3β inhibitors for anti-neuroinflammatory and neuroprotective effects: Synthesis, crystallography, computational analysis, and biological evaluation.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Góral, I.* ; Wichur, T.* ; Sługocka, E.* ; Grygier, P.* ; Głuch-Lutwin, M.* ; Mordyl, B.* ; Honkisz-Orzechowska, E.* ; Szałaj, N.* ; Godyń, J.* ; Panek, D.* ; Zaręba, P.* ; Sarka, A.* ; Żmudzki, P.* ; Latacz, G.* ; Pustelny, K.* ; Bucki, A.* ; Czarna, A.* ; Cardoso Micu Menezes, F.M. ; Więckowska, A.*

Exploring novel GSK-3β inhibitors for anti-neuroinflammatory and neuroprotective effects: Synthesis, crystallography, computational analysis, and biological evaluation.

ACS Chem. Neurosci. 15, 3181-3201 (2024)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

In the pathogenesis of Alzheimer's disease, the overexpression of glycogen synthase kinase-3β (GSK-3β) stands out due to its multifaced nature, as it contributes to the promotion of amyloid β and tau protein accumulation, as well as neuroinflammatory processes. Therefore, in the present study, we have designed, synthesized, and evaluated a new series of GSK-3β inhibitors based on the N-(pyridin-2-yl)cyclopropanecarboxamide scaffold. We identified compound 36, demonstrating an IC₅₀ of 70 nM against GSK-3β. Subsequently, through crystallography studies and quantum mechanical analysis, we elucidated its binding mode and identified the structural features crucial for interactions with the active site of GSK-3β, thereby understanding its inhibitory potency. Compound 36 was effective in the cellular model of hyperphosphorylated tau-induced neurodegeneration, where it restored cell viability after okadaic acid treatment and showed anti-inflammatory activity in the LPS model, significantly reducing NO, IL-6, and TNF-α release. In ADME-tox in vitro studies, we confirmed the beneficial profile of 36, including high permeability in PAMPA (Pe equals 9.4) and high metabolic stability in HLMs as well as lack of significant interactions with isoforms of the CYP enzymes and lack of considerable cytotoxicity on selected cell lines (IC₅₀ > 100 μM on HT-22 cells and 89.3 μM on BV-2 cells). Based on promising pharmacological activities and favorable ADME-tox properties, compound 36 may be considered a promising candidate for in vivo research as well as constitute a reliable starting point for further studies.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Adme ; Alzheimer’s Disease ; Edda ; Anti-inflammatory Activity ; Crystallography ; Glycogen Synthase Kinase-3β ; Neurodegeneration; Alzheimers-disease; Tau Phosphorylation; Tnf-alpha; Synthase; Protein; Model; Brain; Neurodegeneration; Tideglusib; Activation

e-ISSN 1948-7193

Journal ACS Chemical Neuroscience

Quellenangaben Volume: 15, Issue: 17, Pages: 3181-3201

Publisher American Chemical Society (ACS)

Publishing Place 1155 16th St, Nw, Washington, Dc 20036 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Structural Biology (STB)

Grants Smart Growth Operational Programme POIR 4.2 project
qLIFE Priority Research Area under the program "Excellence Initiative-Research University" at Jagiellonian University in Krakow
Jagiellonian University Medical College
National Science Centre Poland